Government health officials on Monday approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. The Food and Drug Administration said it granted approval to the drug from Biogen based on results that seemed "reasonably likely" to benefit Alzheimer's patients. It's the only drug that U.S. regulators have said can likely treat the underlying disease, rather than manage symptoms like anxiety and insomnia. The decision, which could impact millions of older Americans and their families, is certain to spark disagreements among physicians, medical researchers and patient groups. It also has far-reaching implications for the standards used to evaluate experimental therapies, including those that show only incremental benefits. The new drug, which Biogen developed with Japan's Eisai Co., did not reverse mental decline, only slowing it in one study. The medication, aducanumab, will be marketed as Aduhelm and is to be given as an infusion every four weeks. Dr. Caleb Alexander, an FDA adviser who recommended against the drug's approval, said he was "surprised and disappointed" by the decision. "The FDA gets the respect that it does because it has regulatory standards that are based on firm evidence. In this case, I think they gave the product a pass," said Alexander, a researcher at Johns Hopkins University. The FDA's top drug regulator acknowledged in a statement that "residual uncertainties" surround the drug, but said Aduhelm's ability to reduce harmful clumps of plaque in the brain "is expected" to help slow dementia. Under terms of the so-called accelerated approval, the FDA is requiring the drugmaker to conduct a follow-up study to confirm benefits for patients. If the study fails to show effectiveness, the FDA could pull the drug from the market, though the agency rarely does so. Biogen did not immediately disclose the price, though analysts have estimated the drug could cost between $30,000 and $50,000 for a year's worth of treatment. A preliminary analysis by one group found that the drug would need to be priced $2,500 to $8,300 per year to be a good value based on the "small overall health gains" suggested by company studies. The non-profit Institute for Clinical and Economic Review added that "any price is too high" if the drug's benefit isn't confirmed in follow-up studies. Nearly 6 million people in the U.S. and many more worldwide have Alzheimer's, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks. In the final stages of the disease, those afflicted lose the ability to swallow. The global burden of the disease, the most common cause of dementia, is only expected to grow as millions more baby boomers progress further into their 60s and 70s. Aducanumab (pronounced "add-yoo-CAN-yoo-mab") helps clear a protein linked to Alzheimer's, called beta-amyloid, from the brain. Other experimental drugs have done that before but they made no difference in patients' ability to think, care for themselves or live independently. The pharmaceutical industry's drug pipeline has been littered for years with failed Alzheimer's treatments, representing billions in research costs. The FDA's greenlight is likely to revive investments in similar therapies previously shelved by drugmakers. The new medicine is made from living cells that will have to be given via infusion at a doctor's office or hospital. Researchers don't fully understand what causes Alzheimer's but there's broad agreement that the brain plaque targeted by aducanumab is just one factor. Growing evidence suggests family history, education and chronic conditions like diabetes and heart disease may all play a role. "This is just one piece of the puzzle and I think all these other options need to be explored and amplified," said Dr. Ronald Petersen, a Mayo Clinic dementia specialist who has consulted for Biogen and other drugmakers. Patients taking aducanumab saw their thinking skills decline 22% more slowly than patients taking a sham treatment. But that meant a difference of just 0.39 on an 18-point score of cognitive and functional ability. And it's unclear how such metrics translate into practical benefits, like greater independence or ability to recall important details. The FDA's review of the drug has become a flashpoint in longstanding debates over standards used to evaluate therapies for hard-to-treat conditions. On one side, groups representing Alzheimer's patients and their families say any new therapy—even one of small benefit—warrants approval. But many experts have warned that greenlighting the drug could set a dangerous precedent, opening the door to treatments of questionable benefit. The approval came despite a scathing assessment in November by the FDA's outside panel of neurological experts. The group voted "no" to a series of questions on whether reanalyzed data from a single study submitted by Biogen showed that the drug was effective. Cambridge, Massachusetts-Biogen halted two studies of the drug in 2019 after disappointing results suggested aducanumab would not meet its goal of slowing mental and functional decline in Alzheimer's patients. Several months later, the company reversed course, announcing that a new analysis of one of the studies showed the drug was effective at higher doses and that the FDA had advised that it warranted review. Company scientists said the drug's initial failure was due to some patients not receiving high enough doses to slow the disease. But the changes to dosing and the company's after-the-fact analysis made the results hard to interpret, raising the skepticism of many experts, including those on the FDA panel. The FDA isn't required to follow the advice of its outside panelists and has previously disregarded their input when making similarly high-profile drug decisions. About 600 U.S. medical specialists took part in Biogen's studies of the drug and many more are expected to begin offering it. Many practical questions remain unanswered: How long do patients benefit? How do physicians determine when to discontinue the drug? Does the drug have any benefit in patients with more advanced dementia? With FDA approval, aducanumab is certain to be covered by virtually all insurers, including Medicare, the government plan for seniors that covers more than 60 million people. Both the FDA and Medicare are barred from considering cost when reviewing a new drug or treatment. Even qualifying for the drug could be expensive. It's only been tested in people with mild dementia from Alzheimer's or a less severe condition called mild cognitive impairment. To verify a diagnosis could require brain scans that cost $5,000 or more. Insurers including Medicare don't cover the scans because their benefits are unclear, but that could change if the scans become a gateway to treatment. Additional scans will be needed to monitor potential side effects. The drug carries a warning about temporary brain swelling that can sometimes cause headaches, confusion and dizziness. Other side effects included allergic reactions, diarrhea and disorientation. For patients in Biogen's studies, the decision means they can continue taking a drug that many believe has helped. Kevin Bonham was diagnosed with early onset Alzheimer's in 2016 after having difficulties with memory, reading and driving. The 63-year-old from Bear Creek Village, Pennsylvania, credits the drug with helping him keep his job as a mapmaker for another three years. "Very quickly over a period of months it was like the fog was lifted from the top of my head," said Bonham, who is now on disability and relies on his wife, Kim, to help care for him and his teenage daughter. Like other trial participants, Bonham had to stop taking aducanumab in March 2019 after Biogen halted its trials. He resumed infusions nearly a year ago as part of the company's ongoing research. © 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. —Matthew Perrone Source
